Hologic, Inc. (HOLX) and its subsidiary, Biotheranostics, recently presented new research findings. The results suggest that in the absence of Breast Cancer Index (BCI) genetic testing, a significant proportion of early-stage hormone receptor-positive (HR+) breast cancer survivors may have received excessive or insufficient treatment. The study was published in the March issue of the JNCCN — Journal of the National Comprehensive Cancer Network.Previous research has shown that most women with early-stage HR+ ...